1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

TVGNW
Tevogen Bio Holdings Inc.US flagNASDAQ Capital Market
0.04
USD
+0.00
- -
8.69MMarket Cap
Tevogen Bio Holdings Inc.
TVGNW
(NASDAQ Capital Market)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
1
- -
Depreciation Expense
-16
4
-60
-14
-26
-21
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
7
- -
-84
-7
-6
-5
Working Capital
23
40
14
1
6
7
LT Debt
-16
342
-94
-7
-8
-10
Total Equity
- -
-0.49
- -
- -
- -
- -
Return on Invested Capital (%)
- -
2.27
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
4
4
6
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
9
9
9
Shares Outstanding
4
4
4
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
7
Payables & Accruals
5
5
5
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
23.39%
Free Cash Flow
- -
- -
3.29%
Net Income, GAAP
- -
- -
91.41%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Zealand Pharma A/S (ZLDPF)
Palisade Bio, Inc. (PALI)
Graybug Vision, Inc. (GRAY)
CTI BioPharma Corp. (CTIC)
Denali Therapeutics Inc. (DNLI)
EvoNext Holdings S.A. (ELVAF)
Business
Tevogen Bio Holdings Inc. (Nasdaq: TVGNW) is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified precision T cell therapies leveraging its proprietary ExacTcell platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders; key pipeline products include TVGN 489 for high-risk COVID-19 patients including those with B-cell suppression and Long COVID, TVGN 116 for liver cancer prevention in chronic Hepatitis B patients, TVGN 930 for Epstein-Barr virus-related lymphoma, TVGN 920 for uterine cervical cancer, TVGN 601 for multiple sclerosis, and TVGN 960 for otorhinolaryngologic neoplasms, among others in preclinical development. The company, founded in 2020 and headquartered in Warren, New Jersey, targets large patient populations including elderly, high-risk, and immunocompromised individuals across virology, oncology, and neurology segments with a focus on affordability and accessibility. In recent developments, Tevogen expanded its headquarters in Warren, New Jersey in July 2025 fully funded by CEO Ryan Saadi to centralize R&D, regulatory, AI, and executive teams; accepted $1 million in additional non-dilutive grant funding in August 2025 from KRHP LLC toward Tevogen.AI advancement as part of up to $10 million total; partnered with Microsoft through the Microsoft for Startups program in May 2024 and filed predictive AI patent applications in December 2024 to bolster its Tevogen.AI drug discovery platform; and highlighted promising clinical data and revenue projections for TVGN 489 and TVGN 116 while establishing a GMP cell manufacturing facility.